# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 2551-2560 of 2727 results.
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Status: Completed
Last Changed: May 12, 2020
First Received: Oct 04, 2016
Disease(s): Advanced Malignancies, Metastatic Cancer
Intervention(s): INCAGN01949
Locations: Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States
New York University Clinical Cancer Center, New York, New York, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
... and 4 other locations.
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
Status: Completed
Last Changed: Sep 05, 2013
First Received: Aug 31, 2007
Disease(s): Genital Neoplasms, Female
Intervention(s): Topotecan, CCI-779 (temsirolimus)
Locations: University of Chicago, Chicago, Illinois, United States
DOvEEgene Fleur: New Uterine Sampling Tool
Status: Not yet recruiting
Last Changed: Sep 01, 2020
First Received: Feb 06, 2020
Disease(s): Women With Suspected or Confirmed Gynecological Disease
Intervention(s): DOvEEgene Fleur Sampling
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
Status: Completed
Last Changed: Aug 26, 2015
First Received: Jan 27, 2003
Disease(s): Cancer
Intervention(s): filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Locations: City of Hope Comprehensive Cancer Center, Duarte, California, United States
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
Status: Recruiting
Last Changed: Sep 16, 2020
First Received: Aug 16, 2017
Disease(s): Neoplasms
Intervention(s): TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Locations: GSK Investigational Site, Los Angeles, California, United States
GSK Investigational Site, Whittier, California, United States
GSK Investigational Site, Denver, Colorado, United States
GSK Investigational Site, Sarasota, Florida, United States
GSK Investigational Site, Tampa, Florida, United States
... and 9 other locations.
Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors
Status: Completed
Last Changed: Mar 30, 2020
First Received: Jan 25, 2016
Disease(s): Cancer
Intervention(s): blood samples, Urine samples
Locations: CGFL, Dijon, France
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
Status: Unknown status
Last Changed: Feb 24, 2017
First Received: Nov 27, 2014
Disease(s): Carcinoma
Locations: Practice, Mannheim, Germany
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Status: Recruiting
Last Changed: Oct 23, 2020
First Received: Jul 26, 2018
Disease(s): Locally Advanced or Metastatic Solid Tumor
Intervention(s): rebastinib, Paclitaxel
Locations: University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
Scripps Health, San Diego, California, United States
University of Colorado Denver- Anschutz Medical Center, Aurora, Colorado, United States
Smillow Cancer Hospital Care Center at Trumbull, Trumbull, Connecticut, United States
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
... and 13 other locations.
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Status: Recruiting
Last Changed: Jul 31, 2020
First Received: Jul 24, 2020
Disease(s): Solid Tumor, Adult
Intervention(s): TTX-080
Locations: Nebraska Cancer Center Oncology Hematology West P.C., Omaha, Nebraska, United States
NEXT Oncology, San Antonio, Texas, United States
Study of Intermittent OSI-906 Dosing
Status: Completed
Last Changed: Jan 30, 2019
First Received: Aug 09, 2007
Disease(s): Advanced Solid Tumors
Intervention(s): OSI-906
Locations: MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Unit, Royal Marsden Hospital, Sutton, Surrey, United Kingdom